A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together
Journal of the American Chemical Society · 29.01.2025 · 147 (4) · 3110-3118
DOI: 10.1021/jacs.4c11930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 02.12.2024. Verfasst von Yongbo Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology…. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Glioblastoma, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Frontier Research Center for Biological Structure, Tsinghua University.
Abstract (Originalsprache)
Glioblastoma, a highly aggressive brain tumor, lacks effective treatment with low 5 year survival rates. Urgency for new therapies is evident. Mammalian targets of rapamycin (mTOR) and G1 to S phase transition 1 gene (GSPT1) are overexpressed in glioblastoma, regulating vital cellular functions. Current mTOR inhibitors face challenges in clinical efficacy and drug resistance. Similarly, GSPT1-targeting therapies have not progressed of glioblastoma in clinical trials. Research studies suggested that combining mTOR inhibition with GSPT1 degradation may overcome resistance and enhance efficacy. We propose the concept of jointly implementing inhibition and degradation on different proteins, integrating the properties of inhibitors and degraders into the same molecule. Introducing YB-3-17, a novel bifunctional molecule, robustly inhibits mTOR and selectively degrades GSPT1. As a tool compound for proof-of-concept studies, YB-3-17 sharpens selectivity, avoiding off-target effects, and selectively induces GSPT1 degradation and mTOR inhibition, showing superior efficacy in tumor cell lines compared to that of standalone therapies. RNA-seq analysis highlights the advantages of YB-3-17 over mTOR inhibitor treatment. YB-3-17 can safely and effectively inhibit tumor growth in mice, offering a promising direction for precision treatment of glioblastoma, representing the first attempt to combine mTOR inhibition with GSPT1 degradation. This work also demonstrates that it is conceptually possible to successfully combine the properties of small molecule inhibitors and degraders into a single molecule, killing two birds with one stone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, State Key Laboratory of Molecular Oncology, Tsinghua University, Bei…
- Changping Laboratory, Beijing 102206, China.
ORCID-Profile: Yongbo Liu, Xiuyun Sun, Yu Rao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Frontier Research Center for Biological Structure, Tsinghua University
Zitieren
APA
Liu, Y., Sun, X., Liu, Q., Han, C., & Rao, Y. (2025). A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together. Journal of the American Chemical Society, 147(4), 3110-3118. https://doi.org/10.1021/jacs.4c11930
Vancouver
Liu Y, Sun X, Liu Q, Han C, Rao Y. A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together. Journal of the American Chemical Society. 2025;147(4):3110-3118. doi:10.1021/jacs.4c11930
BibTeX
@article{Liu2025,
author = {Liu, Yongbo and Sun, Xiuyun and Liu, Qianlong and Han, Chi and Rao, Yu},
title = {A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together},
journal = {Journal of the American Chemical Society},
year = {2025},
volume = {147},
number = {4},
pages = {3110--3118},
doi = {10.1021/jacs.4c11930}
}
EUVIMED